Payment overview · 2025
General Payments
$560.65
28 reported records · 13 companies
Healthcare provider profile · identity verified
Yoany Guia, MD
Allopathic & Osteopathic Physicians|General Practice · OCALA, FL · NPI 1104275973
Verified facts
What the public records show
CMS Open Payments records show Yoany Guia, MD received $560.65 in general payments during 2025 across 28 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 18.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 192 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 192 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $105.38 | 18.8% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $74.64 | 13.3% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $72.36 | 12.9% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $69.27 | 12.4% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $50.28 | 9.0% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $44.25 | 7.9% | 3 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $30.14 | 5.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $24.09 | 4.3% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $23.54 | 4.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $23.18 | 4.1% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $18.21 | 3.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.75 | 2.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $10.56 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $560.65 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $86.73 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $74.64 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $74.64 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $72.36 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $72.36 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $69.27 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $44.25 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $33.49 | 2 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $30.14 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $24.09 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $23.54 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $23.18 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $18.21 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.79 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.79 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.75 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.75 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $10.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 98 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 20 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 192 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 54 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
39 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
20 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
35 | 16 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
192 | 49 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
54 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
192 | 49 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
94 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
98 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
24 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 805 | 284 |
| Levothyroxine Sodium | Levothyroxine Sodium | 758 | 223 |
| Amlodipine Besylate | Amlodipine Besylate | 727 | 243 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 601 | 202 |
| Losartan Potassium | Losartan Potassium | 557 | 188 |
| Omeprazole | Omeprazole | 505 | 175 |
| Lisinopril | Lisinopril | 478 | 162 |
| Metformin Hcl | Metformin Hcl | 437 | 141 |
| Gabapentin | Gabapentin | 379 | 136 |
| Alprazolam | Alprazolam | 366 | 75 |
| Fluticasone Propionate | Fluticasone Propionate | 308 | 140 |
| Metoprolol Tartrate | Metoprolol Tartrate | 301 | 113 |
| Citalopram Hbr | Citalopram Hydrobromide | 288 | 91 |
| Trazodone Hcl | Trazodone Hcl | 279 | 93 |
| Hydrochlorothiazide | Hydrochlorothiazide | 278 | 85 |
| Azithromycin | Azithromycin | 277 | 216 |
| Pantoprazole Sodium | Pantoprazole Sodium | 271 | 104 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 247 | 87 |
| Simvastatin | Simvastatin | 237 | 82 |
| Meclizine Hcl | Meclizine Hcl | 214 | 80 |
| Glipizide | Glipizide | 211 | 62 |
| Alendronate Sodium | Alendronate Sodium | 208 | 63 |
| Clonazepam | Clonazepam | 202 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 195 | 66 |
| Jardiance | Empagliflozin | 192 | 49 |
| Carvedilol | Carvedilol | 185 | 62 |
| Furosemide | Furosemide | 184 | 61 |
| Pravastatin Sodium | Pravastatin Sodium | 182 | 58 |
| Famotidine | Famotidine | 175 | 64 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 166 | 95 |
| Zolpidem Tartrate | Zolpidem Tartrate | 154 | 33 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 151 | 113 |
| Montelukast Sodium | Montelukast Sodium | 147 | 59 |
| Sertraline Hcl | Sertraline Hcl | 146 | 44 |
| Prednisone | Prednisone | 144 | 115 |
| Meloxicam | Meloxicam | 137 | 40 |
| Tizanidine Hcl | Tizanidine Hcl | 137 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 135 | 55 |
| Atenolol | Atenolol | 121 | 35 |
| Temazepam | Temazepam | 115 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 113 | 28 |
| Tramadol Hcl | Tramadol Hcl | 106 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 104 | 37 |
| Clonidine Hcl | Clonidine Hcl | 102 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 102 | 31 |
| Eliquis | Apixaban | 98 | 31 |
| Valsartan | Valsartan | 95 | 34 |
| Ozempic | Semaglutide | 94 | 24 |
| Donepezil Hcl | Donepezil Hcl | 92 | 31 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 90 | 28 |
| Glimepiride | Glimepiride | 89 | 35 |
| Hydralazine Hcl | Hydralazine Hcl | 88 | 30 |
| Januvia | Sitagliptin Phosphate | 85 | 24 |
| Mupirocin | Mupirocin | 85 | 61 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 83 | 33 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 83 | 31 |
| Pregabalin | Pregabalin | 81 | 14 |
| Allopurinol | Allopurinol | 78 | 29 |
| Potassium Chloride | Potassium Chloride | 77 | 28 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 75 | 28 |
| Amoxicillin | Amoxicillin | 73 | 66 |
| Diclofenac Sodium | Diclofenac Sodium | 70 | 23 |
| Lovastatin | Lovastatin | 70 | 21 |
| Bupropion Hcl Sr | Bupropion Hcl | 65 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 64 | 27 |
| Eszopiclone | Eszopiclone | 64 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 64 | 18 |
| Naproxen | Naproxen | 63 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 62 | 18 |
| Celecoxib | Celecoxib | 61 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 60 | 26 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 56 | 15 |
| Ofloxacin | Ofloxacin | 56 | 46 |
| Lorazepam | Lorazepam | 55 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 55 | 20 |
| Baclofen | Baclofen | 54 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 54 | 12 |
| Methocarbamol | Methocarbamol | 53 | 11 |
| Benazepril Hcl | Benazepril Hcl | 52 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 52 | 14 |
| Benzonatate | Benzonatate | 50 | 37 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 50 | 22 |
| Metformin Hcl Er | Metformin Hcl | 49 | 20 |
| Cephalexin | Cephalexin | 47 | 41 |
| Ezetimibe | Ezetimibe | 46 | 18 |
| Nifedipine Er | Nifedipine | 45 | 13 |
| Ondansetron Odt | Ondansetron | 44 | 29 |
| Ropinirole Hcl | Ropinirole Hcl | 44 | 11 |
| Ciclopirox | Ciclopirox | 43 | 22 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 43 | 30 |
| Glipizide Er | Glipizide | 43 | 15 |
| Myrbetriq | Mirabegron | 43 | 15 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 42 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | 14 |
| Sildenafil Citrate | Sildenafil Citrate | 41 | suppressed |
| Spironolactone | Spironolactone | 41 | 15 |
| Finasteride | Finasteride | 40 | 15 |
| Ketoconazole | Ketoconazole | 40 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 40 | 12 |
| Fenofibrate | Fenofibrate | 39 | 13 |
| Synthroid | Levothyroxine Sodium | 39 | 12 |
| Enalapril Maleate | Enalapril Maleate | 37 | 14 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 37 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 36 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 35 | 16 |
| Latanoprost | Latanoprost | 33 | suppressed |
| Memantine Hcl | Memantine Hcl | 31 | 11 |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 29 | suppressed |
| Ibuprofen | Ibuprofen | 29 | 15 |
| Rybelsus | Semaglutide | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 27 | suppressed |
| Gemfibrozil | Gemfibrozil | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | 11 |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 23 |
| Hydrocortisone | Hydrocortisone | 24 | 15 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | 12 |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 24 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 23 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Sotalol | Sotalol Hcl | 23 | suppressed |
| Timolol Maleate | Timolol Maleate | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Tradjenta | Linagliptin | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | 12 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 20 | suppressed |
| Diazepam | Diazepam | 20 | 14 |
| Farxiga | Dapagliflozin Propanediol | 20 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | 13 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 17 | 17 |
| Epinephrine | Epinephrine | 17 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Comfort Ez Insulin Syringe | Syringe And Needle,insulin,1ml | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 15 |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Novolin R | Insulin Regular, Human | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Clotrimazole | Clotrimazole | 14 | 12 |
| Fluocinolone Acetonide Oil | Fluocinolone Acetonide Oil | 14 | suppressed |
| Letrozole | Letrozole | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | 11 |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Armour Thyroid | Thyroid,pork | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Klor-Con 8 | Potassium Chloride | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $560.65 · 28 records | Boehringer Ingelheim Pharmaceuticals, Inc. | AREXVY, ELIQUIS, FARXIGA, General - Pain Management, JARDIANCE, Kerendia, Korlym, LUMRYZ, MOUNJARO, NURTEC ODT, OTEZLA, REPATHA, SHINGRIX, TRELEGY ELLIPTA, VOQUEZNA, VRAYLAR, Wegovy, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error